赛升药业
(300485)
| 流通市值：23.69亿 | | | 总市值：41.66亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 93,412,526.91 | 134,458,493.24 | 88,134,170.56 | 90,809,825.65 |
| 交易性金融资产 | 1,379,101,562.73 | 1,486,479,551.54 | 1,473,900,144.47 | 1,564,374,207.48 |
| 应收票据及应收账款 | 39,975,324.24 | 40,506,857.16 | 44,874,987.15 | 47,798,784.17 |
| 其中：应收票据 | 2,731,518.87 | 1,579,872.98 | 2,476,306.12 | 2,536,215.43 |
| 应收账款 | 37,243,805.37 | 38,926,984.18 | 42,398,681.03 | 45,262,568.74 |
| 预付款项 | 482,738.2 | 133,184.8 | 19,713.8 | 451,295.24 |
| 其他应收款合计 | 894,842.02 | 987,729.54 | 948,161.59 | 988,002.48 |
| 存货 | 70,911,640.62 | 71,563,801.64 | 68,850,757.57 | 72,702,985.36 |
| 其他流动资产 | 10,275,346.6 | 17,046,991.46 | 10,802,498.14 | 3,308,715.19 |
| 流动资产合计 | 1,595,053,981.32 | 1,751,176,609.38 | 1,687,530,433.28 | 1,780,433,815.57 |
| 非流动资产: | | | | |
| 长期股权投资 | 606,212,726.5 | 652,167,185.46 | 709,580,877.36 | 711,097,501.5 |
| 其他非流动金融资产 | 218,350,987.63 | 222,652,710.75 | 223,649,698.99 | 233,840,614.97 |
| 固定资产 | 425,021,050.39 | 433,403,344.72 | 438,447,032.63 | 444,317,358.55 |
| 在建工程 | 20,088,757.84 | 11,293,481.7 | 11,293,481.7 | 11,293,481.7 |
| 生产性生物资产 | 13,675,166.41 | 13,685,144.51 | 13,760,630.91 | 7,455,473.41 |
| 使用权资产 | 11,167,517.35 | 11,255,220.37 | 11,342,923.39 | 11,430,626.41 |
| 无形资产 | 43,507,491.65 | 44,052,431.07 | 44,679,819.05 | 44,161,489.24 |
| 开发支出 | 372,182,767.65 | 369,167,077.55 | 366,905,803.63 | 336,234,548.02 |
| 商誉 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 |
| 递延所得税资产 | 1,788,886.15 | 2,169,916.02 | 2,282,959.52 | 1,886,605.55 |
| 其他非流动资产 | 33,519,547 | 32,851,210.06 | 37,064,000.33 | 730,586.06 |
| 非流动资产合计 | 1,767,379,986.39 | 1,814,562,810.03 | 1,880,872,315.33 | 1,824,313,373.23 |
| 资产总计 | 3,362,433,967.71 | 3,565,739,419.41 | 3,568,402,748.61 | 3,604,747,188.8 |
| 流动负债: | | | | |
| 短期借款 | 14,258,958.12 | 19,680,640 | 19,858,585.77 | 19,987,800 |
| 交易性金融负债 | - | 127,831.79 | 127,831.79 | - |
| 应付票据及应付账款 | 12,481,155.34 | 12,696,335.92 | 22,629,265.51 | 13,868,098.96 |
| 应付账款 | 12,481,155.34 | 12,696,335.92 | 22,629,265.51 | 13,868,098.96 |
| 预收款项 | 275,229.36 | 585,017.76 | 600,708.29 | - |
| 合同负债 | 9,103,380.7 | 7,125,607.62 | 4,323,472.85 | 5,642,972.29 |
| 应付职工薪酬 | 4,305,710.49 | 4,302,763.75 | 4,315,768.98 | 4,261,563.19 |
| 应交税费 | 3,235,504.67 | 2,519,212.28 | 1,994,268.25 | 4,781,205.99 |
| 其他应付款合计 | 30,301,228.32 | 39,556,317.67 | 38,016,545.28 | 32,409,697.64 |
| 其他流动负债 | 1,183,439.5 | 575,840.51 | 430,901.03 | 733,586.4 |
| 流动负债合计 | 75,144,606.5 | 87,169,567.3 | 92,297,347.75 | 81,684,924.47 |
| 非流动负债: | | | | |
| 递延收益 | 680,718.98 | 680,718.98 | 420,718.98 | 1,438,970.28 |
| 递延所得税负债 | 55,308,124.99 | 82,024,984.38 | 83,235,472.85 | 88,135,974.86 |
| 非流动负债合计 | 55,988,843.97 | 82,705,703.36 | 83,656,191.83 | 89,574,945.14 |
| 负债合计 | 131,133,450.47 | 169,875,270.66 | 175,953,539.58 | 171,259,869.61 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 481,666,400 | 481,666,400 | 481,666,400 | 481,666,400 |
| 资本公积 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 |
| 其他综合收益 | -50,592.91 | 346,438.29 | 746,764.87 | 1,023,499.18 |
| 盈余公积 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 |
| 未分配利润 | 1,639,837,527.77 | 1,802,614,488.05 | 1,797,951,199.89 | 1,835,239,767.5 |
| 归属于母公司股东权益合计 | 3,212,063,925.3 | 3,375,237,916.78 | 3,370,974,955.2 | 3,408,540,257.12 |
| 少数股东权益 | 19,236,591.94 | 20,626,231.97 | 21,474,253.83 | 24,947,062.07 |
| 股东权益合计 | 3,231,300,517.24 | 3,395,864,148.75 | 3,392,449,209.03 | 3,433,487,319.19 |
| 负债和股东权益合计 | 3,362,433,967.71 | 3,565,739,419.41 | 3,568,402,748.61 | 3,604,747,188.8 |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-03-31 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |